https://www.selleckchem.com/pr....oducts/deferiprone.h
Respiratory distress syndrome (RDS) is a common neonatal condition in premature infants. Its treatment often requires the use of surfactants. The administration of surfactants has evolved to less invasive surfactant administration (LISA) methods in recent years. Nasal high frequency oscillatory ventilation (nHFOV) is also a good new technology for respiratory support. The use of LISA combined with nHFOV for RDS has not been reported. A 970 g male infant who was born at 29 weeks of gestational age suffered progressive dyspnea immedia
Like
Comment
Share
